Inventor · disambiguated record
Mark R. Brann
Also filed as: BRANN MARK · BRANN MARK R · BRANN MARK ROBERT
31 granted patents·18 pending applications·1,255 citations·filing 1989–2021
98Inventor score
Top patents by PatentIndex Score
49 records- 0198US8921393B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2013·Granted Dec 30, 2014·41 cites·36 claims
- 0297US10028944B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2017·Granted Jul 24, 2018·15 cites·15 claims
- 0397US9566271B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2015·Granted Feb 14, 2017·17 cites·15 claims
- 0497US8377959B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2012·Granted Feb 19, 2013·26 cites·12 claims
- 0597US8008323B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2010·Granted Aug 30, 2011·25 cites·9 claims
- 0697US7994193B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2010·Granted Aug 9, 2011·29 cites·9 claims
- 0797US7732462B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2006·Granted Jun 8, 2010·36 cites·24 claims
- 0897US7659285B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2006·Granted Feb 9, 2010·33 cites·11 claims
- 0997US7601740B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2004·Granted Oct 13, 2009·60 cites·26 claims
- 1096US10525046B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2018·Granted Jan 7, 2020·12 cites·20 claims
- 1196US9211289B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2014·Granted Dec 15, 2015·20 cites·13 claims
- 1296US7713995B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2006·Granted May 11, 2010·30 cites·15 claims
- 1395US8618130B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2013·Granted Dec 31, 2013·25 cites·15 claims
- 1495US7863296B2Selective serotonin receptor inverse agonists as therapeutics for diseaseACADIA PHARM INC·Filed 2005·Granted Jan 4, 2011·47 cites·18 claims
- 1595US5707798AIdentification of ligands by selective amplification of cells transfected with receptorsRECEPTOR TECHN INC·Filed 1994·Granted Jan 13, 1998·177 cites·41 claims
- 1694US8227487B2Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseasesWEINER DAVID M·Filed 2011·Granted Jul 24, 2012·25 cites·12 claims
- 1794US7875632B2Selective serotonin receptor inverse agonists as therapeutics for diseaseACADIA PHARM INC·Filed 2009·Granted Jan 25, 2011·23 cites·11 claims
- 1893US6528529B1Compounds with activity on muscarinic receptorsACADIA PHARM INC·Filed 1999·Granted Mar 4, 2003·195 cites·88 claims
- 1993US5955281AIdentification of ligands by selective amplification of cells transfected with receptorsACADIA PHARM INC·Filed 1997·Granted Sep 21, 1999·103 cites·13 claims
- 2093US5912132AIdentification of ligands by selective amplification of cells transfected with receptorsACADIA PHARM INC·Filed 1997·Granted Jun 15, 1999·103 cites·14 claims
- 2191US6358698B1Methods of identifying inverse agonists of the serotonin 2A receptorACADIA PHARMACUETICALS INC·Filed 1999·Granted Mar 19, 2002·131 cites·11 claims
- 2287US7820695B2Selective serotonin receptor inverse agonists as therapeutics for diseaseACADIA PHARM INC·Filed 2004·Granted Oct 26, 2010·25 cites·13 claims
- 2386US9050343B2Combination of pimavanserin and risperidone for the treatment of psychosisPETERS PERRY·Filed 2013·Granted Jun 9, 2015·30 cites·6 claims
- 2481US2022241265A1Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2021·Application pending·0 cites
- 2579US2024091212A1Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2021·Application pending·0 cites
- 2678US2020323836A1Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseasesACADIA PHARM INC·Filed 2019·Application pending·0 cites
- 2776US7348140B1Clinical indications for genotyping polymorphic variants of G-protein coupled receptorsACADIA PHARM INC·Filed 2002·Granted Mar 25, 2008·8 cites·4 claims
- 2867US7491503B2Identification of ligands by selective amplification of cells transfected with receptorsACADIA PHARM INC·Filed 2006·Granted Feb 17, 2009·0 cites·12 claims
- 2967US7452682B2Identification of 5HT2A receptor ligands by selective amplification of cells transfected with receptorsACADIA PHARM INC·Filed 2006·Granted Nov 18, 2008·0 cites·9 claims
- 3063US2006199807A1Use of N-desmethylclozapine to treat human neuropsychia tric diseaseWEINER DAVID M·Filed 2006·Application pending·0 cites
- 3163US2006194831A1Use of N-desmethylclozapine to treat human neuropsychiatric diseaseWEINER DAVID M·Filed 2006·Application pending·0 cites
- 3262US2005148018A1Methods of identifying inverse agonists of the serotonin 2A receptorFiled 2005·Application pending·0 cites
- 3360US2005250767A1Use of N-desmethylclozapine to treat human neuropsychiatric diseaseWEINER DAVID M·Filed 2005·Application pending·0 cites
- 3459US2009018119A1Use of n-desmethylclozapine to treat human neuropsychiatric diseaseACADIA PHARM INC·Filed 2008·Application pending·0 cites
- 3557US2008108618A1Compounds with activity on muscarinic receptorsBRANN MARK·Filed 2007·Application pending·0 cites
- 3656US2008051429A1Use of 4-amino-piperidines for treating sleep disordersVAN KAMMEN DANIEL·Filed 2007·Application pending·0 cites
- 3756US2005085463A1Use of N-desmethylclozapine to treat human neuropsychiatric diseaseFiled 2004·Application pending·0 cites
- 3855US2007275957A1Use of n-desmethylclozapine to treat human neuropsychiatric diseaseWEINER DAVID M·Filed 2007·Application pending·0 cites
- 3955US2009053329A1Combinations of 5-ht2a inverse agonists and antagonists with antipsychoticsACADIA PHARM INC·Filed 2008·Application pending·0 cites
- 4054US7425420B2Identification of ligands by selective amplification of cells transfected with a 5HT2A receptorACADIA PHARM INC·Filed 2005·Granted Sep 16, 2008·0 cites·65 claims
- 4153US2005261278A1Selective serotonin receptor inverse agonists as therapeutics for diseaseWEINER DAVID M·Filed 2004·Application pending·0 cites
- 4252US5747336ACloned human genes for muscarinic acetylcholine receptors and cells lines expressing sameUS ARMY·Filed 1994·Granted May 5, 1998·13 cites·8 claims
- 4352US2009156501A1Identification of ligands by selective amplification of cells transfected with receptorsACADIA PHARM INC·Filed 2009·Application pending·0 cites
- 4452US2004224942A1Use of N-desmethylclozapine to treat human neuropsychiatric diseaseFiled 2004·Application pending·0 cites
- 4550US5554500ACloned genes for human dopamine D2 receptors and cell lines expressing sameUS HEALTH·Filed 1989·Granted Sep 10, 1996·6 cites·3 claims
- 4648US2009209525A1Enabling methods to identify allosteric modulators of receptor activitySPALDING TRACY A·Filed 2008·Application pending·0 cites
- 4747US7485651B2Compounds with activity on muscarinic receptorsACADIA PHARM INC·Filed 2003·Granted Feb 3, 2009·0 cites·20 claims
- 4841US2015231126A1Combinations of 5-ht2a inverse agonists and antagonists with antipsychoticsACADIA PHARM INC·Filed 2015·Application pending·0 cites
- 4933US6214615B1Cloned genes for human dopamine D2 receptors and cell lines expressing sameUS HEALTH·Filed 1996·Granted Apr 10, 2001·0 cites·11 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →